Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives
Pharmaceutics · 22.08.2025 · 17 (9) · 1091
DOI: 10.3390/pharmaceutics17091091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 22.08.2025. Verfasst von Devesh U Kapoor und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Dr. Dayaram Patel Pharmacy College, Bardoli 394601, Gujarat, India. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer remains a foremost cause of cancer-related impermanence globally, demanding innovative and effective therapeutic strategies. Polymeric nanoparticles (NPs) have turned up as a promising transport system for drugs due to their biodegradability, biocompatibility, and capability to provide controlled and targeted release of therapeutic agents. This review offers a thorough examination of different polymeric NP platforms, such as chitosan, gelatin, alginate, poly (lactic acid), and polycaprolactone, highlighting their mechanisms, formulations, and applications in the treatment of lung cancer. These NPs facilitate the delivery of chemotherapeutic agents, gene therapies, and immune modulators, with enhanced bioavailability and reduced systemic toxicity. Additionally, advanced formulations such as ligand-conjugated, stimuli-responsive, and multifunctional NPs demonstrate improved tumor-specific accumulation and cellular uptake. The review also discusses quantum dots, magnetic and lipid-based NPs, and green-synthesized metallic polymeric hybrids, emphasizing their potential in theranostics and combination therapies. Preclinical studies show promising results, yet clinical translation faces challenges; for example, large-scale production, long-term toxicity, and regulatory hurdles. Overall, polymeric NPs represent a powerful platform for advancing personalized lung cancer therapy, with future prospects rooted in multifunctional, targeted, and patient-specific nanomedicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, Dr. Dayaram Patel Pharmacy College, Bardoli 394601, Gujarat, India.
- Department of Pharmaceutics, Shree Dhanvantary Pharmacy College, Dist-Kim, Olpad 394110, Gujarat, India.
- PQE Australia Pvt. Ltd., Melbourne, VIC 300, Australia.
- Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Waghodia, Vadodara 391760, Gujarat, India.
- Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand.
- Centre for Research Impact and Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.
ORCID-Profile: Devesh U Kapoor, Bhupendra G Prajapati, Supachoke Mangmool, Sudarshan Singh, Chuda Chittasupho
Zitieren
APA
Kapoor, D. U., Gandhi, S. M., Swarn, S., Lal, B., Prajapati, B. G., Khondee, S., Mangmool, S., Singh, S., & Chittasupho, C. (2025). Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives. Pharmaceutics, 17(9), 1091. https://doi.org/10.3390/pharmaceutics17091091
Vancouver
Kapoor DU, Gandhi SM, Swarn S, Lal B, Prajapati BG, Khondee S, et al. Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives. Pharmaceutics. 2025;17(9):1091. doi:10.3390/pharmaceutics17091091
BibTeX
@article{Kapoor2025,
author = {Kapoor, Devesh U and Gandhi, Sonam M and Swarn, Sambhavi and Lal, Basant and Prajapati, Bhupendra G and Khondee, Supang and Mangmool, Supachoke and Singh, Sudarshan and Chittasupho, Chuda},
title = {Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1091},
doi = {10.3390/pharmaceutics17091091}
}
EUVIMED